Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Allison Sealund

Physician Assistant Dover, DE Physician Assistant

NPI 1497060552 CMS profile 10616356

285 Beiser Blvd Ste 201, Dover, DE 19904

Open in the dashboard

General payments

$420

10 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Sealund of Dover, DE is reported in the CMS Open Payments database as having received $420 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $207 3
2023 General $39 2
2022 General $47 1
2021 General $127 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Sealund
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Allison Sealund were reported at $207. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Allison Sealund Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $127 $132 $37–$438 $132
2022 $47 $155 $48–$522 $149
2023 $39 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $207 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $208 3 payments
  2. Flexion Therapeutics, Inc. $106 3 payments
  3. SI-BONE, Inc. $47 1 payment
  4. Heron Therapeutics, Inc. $24 1 payment
  5. Vertex Pharmaceuticals Incorporated $20 1 payment
  6. Bioventus LLC $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $245 9 payments
  2. Consulting Fee $175 1 payment
Products named General payments · program years 2021–2025
  1. Prolia $196 2 payments
  2. Zilretta $106 3 payments
  3. EVENITY $33 2 payments
  4. ZYNRELEF $24 1 payment
  5. JOURNAVX $20 1 payment
  6. Durolane $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

251

Median for Physician Assistant: 241

Drug cost

$1,492

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 80 $588
Meloxicam Generic 57 $316
Oxycodone Hcl Generic 35 $156
Sulindac Generic 11 $144
Cyclobenzaprine Hcl Generic 25 $129
Gabapentin Generic 28 $126
Tramadol Hcl Generic 15 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$253,307

Of which drugs: $130,486

Medicare patients

770

Average age 75

Services billed

18,300

489 women, 281 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 32%
Chronic kidney disease 30%
Depression 26%
COPD 21%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 36 3,168 $43,303
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 66 7,650 $42,508
Injection, denosumab, 1 mg J0897 Office 14 1,140 $23,186
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 11 19 $10,098
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 401 3,749 $2,802
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 55 75 $363

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record